ETRA
NASDAQ HealthcareElectra Therapeutics, Inc. - Common stock
Biotechnology
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
🎯 投资策略评分
ETRA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (65/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 ETRA in your text
粘贴任何文章、记录或帖子 — 工具将提取 ETRA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-10-29.